Stephen Elmore, MD
Rheumatology · Gainesville, GANPI 1467891564
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 1,062 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 25.2% of the total.
Across 1,062 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Amgen$3K
- UCB, Inc.$2K
- Novartis$2K
- Pfizer$1K
- Johnson & Johnson$918
- plus $5K from 27 others
What the payments were for
- Food & beverage$17,979100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 296 | $4,542 |
| Amgen(2 entities) | 144 | $2,768 |
| UCB, Inc. | 136 | $2,029 |
| Novartis | 88 | $1,504 |
| Pfizer | 71 | $1,219 |
| Johnson & Johnson | 51 | $918 |
| AstraZeneca(2 entities) | 36 | $704 |
| E.r. Squibb & Sons, L.L.C. | 35 | $592 |
| Sanofi | 33 | $577 |
| GSK | 22 | $433 |
| Lilly USA, LLC | 24 | $397 |
| Aurinia Pharma U.S., Inc. | 26 | $397 |
| Genentech USA, Inc. | 15 | $297 |
| Organon | 12 | $258 |
| Radius Health, Inc. | 9 | $225 |
| Sobi, Inc | 11 | $198 |
| Bristol Myers Squibb | 15 | $198 |
| Octapharma USA, Inc. | 6 | $130 |
| Sandoz | 4 | $88 |
| ANI Pharmaceuticals, Inc. | 3 | $71 |
| Fresenius Kabi USA, LLC | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Invivyd Inc | 2 | $41 |
| Merck | 3 | $41 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 2 | $37 |
| Grifols USA, LLC | 2 | $37 |
| Medexus Pharma, Inc. | 3 | $36 |
| Boston Scientific | 1 | $31 |
| Scilex Pharmaceuticals Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
How this compares
$17,998 in reported general payments places this provider in the 75th percentile of 177 rheumatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 171 | $1,334,570 |
| Humira(Cf) PenAdalimumab | 190 | $1,313,155 |
| Orencia ClickjectAbatacept | 161 | $915,345 |
| RinvoqUpadacitinib | 64 | $401,601 |
| KevzaraSarilumab | 57 | $292,460 |
| StelaraUstekinumab | 12 | $281,664 |
| Taltz AutoinjectorIxekizumab | 39 | $267,378 |
| Cimzia (2 Pack)Certolizumab Pegol | 39 | $220,786 |
| Actemra ActpenTocilizumab | 43 | $190,787 |
| ActemraTocilizumab | 37 | $168,064 |
| Xeljanz XrTofacitinib Citrate | 26 | $147,047 |
| Cosentyx Sensoready PenSecukinumab | 15 | $133,116 |
| Humira(Cf)Adalimumab | 18 | $124,400 |
| OtezlaApremilast | 18 | $72,024 |
| Hydroxychloroquine Sulfate | 949 | $39,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $4,542 | $526,00182 claims |
| SanofiKevzara | $577 | $292,46057 claims |
| Johnson & JohnsonStelara | $918 | $281,66412 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,029 | $220,78639 claims |
| AmgenOtezla | $2,768 | $72,02418 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $25 | $3,24034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 rheumatology providers in Georgia.
Other rheumatology in Gainesville
- Brent FlickingerGainesville$20K
- Marta BognarGainesville$20K
- William ChafinGainesville$18K
- Huma SohailGainesville$14K
- James MossellTifton$1.6M
- Gary MyersonAtlanta$1M
- Theresa Lawrence FordLawrenceville$410K
- William WilsonAtlanta$344K
- Jefrey LiebermanDecatur$247K
- Mohammed AbubakerMarietta$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.